Market Overview:
According to the DataM market research report, the Global Hemophilia Market size reached US$ 11,723.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 18,323.9 million by 2030. The hemophilia market is expected to exhibit a CAGR of 5.9% during the forecast period (2023-2030). Hemophilia is induced by a genetic deficiency of a coagulation element that delays blood clotting owing to the lack of sufficient blood-clotting proteins.
Hemophilia is generally treated employing drugs, replacement treatment, and injections of a clotting factor or plasma. Hemophilia treatment concentrates on superseding absent proteins and averting intricacies. The global hemophilia market is segmented on the basis of disease type, product type, therapy, and region.
North America is estimated to hold around 40.6% of the global hemophilia market owing to the high prevalence and government initiative. The major global players in the market include Bayer AG, BioMarin Pharmaceutical, Inc., CSL Behring, Kedrion S.p.A, Novo Nordisk, Pfizer, Inc., Roche (Chugai Pharmaceutical Co.), Sanofi (Genzyme Corporation), and Takeda Pharmaceutical (Shire Plc.), and Grifols among others.
Market Drivers:
Government authorities are taking initiatives to introduce new products for better management of hemophilia treatment. Thus, increasing the number of product approvals is likely to drive the growth of the market. For instance, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec) in November 2022. It is a gene therapy that uses an adeno-associated virus vector to treat Hemophilia B, a condition characterized by congenital Factor IX deficiency in adults. Factor IX protein increases blood levels of Factor IX and thus limits bleeding. The National Hemophilia Foundation (NHF) is actively working to upspring awareness regarding symptoms, diagnosis, and treatment of hemophilia A.
Market Restraints:
The hemophilia drugs are expensive, which restricts a large population to afford the treatment. For instance, the expense of annual drug treatment for an individual with hemophilia is around several hundred thousand USD, and for patients with the most extreme states of the disorder, the yearly therapy expenses of USD 1 million or more.
Market Opportunities:
The development of novel therapies and gene therapies for the treatment of hemophilia. Advancements in genetic engineering and gene therapy technologies offer potential breakthroughs in addressing the underlying causes of hemophilia, aiming to provide long-term or even curative treatments. These innovative approaches have shown promising results in clinical trials, presenting a transformative opportunity in the hemophilia market.
For more details on this report – Request for Sample
Artificial Intelligence Impact Analysis
AI is largely utilized in the design and development of new treatment options for hemophilia, positively impacting the global hemophilia market growth in the forthcoming years. For instance, the Duke University Durham, NC projects considered for Pfizer funding will concentrate on employing Machine Learning/Artificial Intelligence in developing treatments with an emphasis on arising probable one-time therapies like genetic medicine/gene transfer.
Russia-Ukraine Conflict Analysis:
The Russia-Ukraine war had a negative influence on the market as because of the conflict, patients from Ukraine and neighboring provinces were unable to receive care; however, various organizations stood up and tried to help the individuals. For instance, the World Federation of Hemophilia teams is closely monitoring the situation to best support those who are affected via cooperating with national member organizations (NMOs), hemophilia treatment centers (HTCs), and additional stakeholders in Ukraine and neighboring nations that are influenced by the dispute.
Recent Developments in the Industry:
- In July 2022, EMA instructed awarding a conditional commercializing license in the European Union (EU) for Roctavian (valoctocogene roxaparvovec) for the therapy of extreme hemophilia A in adults who lack factor VIII inhibitors (auto-antibodies elicited by the immune system making factor VIII medicines less useful) and no antibodies to adeno-associated virus serotype 5 (AAV5).
- In February 2023, the U.S. Food and Drug Administration (FDA) authorized Sanofi’s ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement treatment and is meant for periodic prophylaxis and on-demand therapy to arrest bleeding attacks, and as perioperative management (surgery) for adults and children with hemophilia A.
- In March 2022, Freeline Therapeutics Holdings, a foremost biotechnology corporation concentrated on visionary liver-directed gene treatments for bleeding conditions and additional debilitating, chronic diseases, dosed the first patient in its Phase I/II B-LIEVE dose-confirmation clinical investigation of FLT180a for the therapy of hemophilia B, a debilitating genetic bleeding disease induced by a lack in the clotting factor IX protein.
Market Segmentation:
As per the research analysis, the global hemophilia market is segmented by disease type into hemophilia A, hemophilia B, and others; by product type into recombinant coagulation, factor concentrates, plasma-derived coagulation, and others; by therapy into replacement therapy, gene therapy, and immune tolerance induction therapy.
- Based on the disease type, owing to the high prevalence and increasing market developments, the hemophilia A segment is estimated to hold around 48.2% of the total hemophilia treatment market by 2030. For instance, according to the NIH, Hemophilia A is the highly common genetic condition of hemostasis, transpires in one out of 5000 men, and makes up 80% of hemophilia patients.
Hemophilia A surfaces in over 400000 males globally; a majority of those stay undiagnosed in developing nations. Moreover, in 2022, Takeda Pharmaceutical Company Limited, a Japanese global pharmaceutical corporation, introduced Adynovate, a prolonged half-life recombinant Factor VIII (rFVIII) therapy for hemophilia A suffering individuals in India.
Geographical Classification:
The global hemophilia market is segmented into North America, Europe, South America, Asia Pacific, and Middle East & Africa.
North America Hemophilia Market:
North America is estimated to hold around 40.6% of the global hemophilia market owing to the high prevalence and government initiative. For instance, in August 2022, according to the U.S. Centers for Disease Control and Prevention (CDC), approximately 33,000 individuals in the U.S. had hemophilia. Hemophilia generally involves men and individuals assigned male at birth (AMAB).
Moreover, the task of the CDC’s Division of Blood Disorders is to lower the morbidity and mortality from blood conditions via an extensive public health approach. CDC is especially positioned to lower the public health load of bleeding conditions like hemophilia.
Market Key Players
The major global players in the market include Bayer AG, BioMarin Pharmaceutical, Inc., CSL Behring, Kedrion S.p.A, Novo Nordisk, Pfizer, Inc., Roche (Chugai Pharmaceutical Co.), Sanofi (Genzyme Corporation), and Takeda Pharmaceutical (Shire Plc.), and Grifols among others.
Suggestions for Related Report
For more Pharmaceutical-related reports, please click here.
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regard to the scope offered will be addressed within 24- 48 hours.
3) An Excel sheet with market numbers will be provided separately.
The Full Report has the below insights:
- The report offers a comprehensive evaluation of the market in terms of market value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2021-2022) and verifiable projections about market size during the forecast period (2023-2030).
- Visualize the composition of the global hemophilia market by disease type, product type, therapy, and region, highlighting the key commercial assets and players.
- By Disease Type: Hemophilia A, Hemophilia B, Others
- By Product Type: Recombinant Coagulation, Factor Concentrates, Plasma-derived Coagulation, Other
- By Therapy: Replacement Therapy, Gene Therapy, Immune Tolerance Induction Therapy
- By Region: North America, South America, Europe, Asia Pacific, Middle East & Africa
- Identify commercial opportunities in the global hemophilia market by analyzing trends and co-development deals.
- The report also covers data insights on various industry forces such as Porter’s five forces analysis, supply chain analysis, pricing analysis, regulatory analysis.
- Excel data sheet with thousands of data points of global hemophilia market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in Excel for the key product of all major market players
The report will provide access to approximately 61 market data tables, 64 figures and close to 180 pages.
About Us:
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you.
We encompass a multitude of Syndicate Reports & Customized Reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.